ONCAlert | Upfront Therapy for mRCC

Prostate Cancer VIEW MORE >>

In an interview with Targeted Oncology, Maha Hussain, MD, discussed targeting DNA repair defects in mCRPC with the PARP inhibitor olaparib in the phase III PROfound trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.